Telix Pharmaceuticals (TLX) Equity Ratio (2023 - 2024)
Telix Pharmaceuticals (TLX) posted Equity Ratio of 0.37 for Q4 2024, up 2.15% on a QoQ basis from 0.37 in Q4 2023, and up 2.15% year-over-year from 0.37 in Q1 2024.
Telix Pharmaceuticals (TLX) has 2 years of Equity Ratio data on file, last reported at 0.37 in Q4 2024.
- In Q4 2024, Equity Ratio rose 2.15% year-over-year to 0.37; the TTM figure through Dec 2024 stood at 0.37 (up 2.15% YoY), while the FY2024 annual figure was 0.37, up 2.15% from the prior year.
- Equity Ratio advanced to 0.37 in Q4 2024, from 0.37 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.37 in Q4 2024 and bottomed at 0.37 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 0.04 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.42 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.73 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.77 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.21 |
| 10 | Telix Pharmaceuticals | 4.52 Bn | 4.38 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 0.37 |
| Dec 31, 2023 | 0.37 |